Breakthrough's Achilles Heel: Alexion’s Newly Acquired Kanuma Delayed By Manufacturing
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA extends the PDUFA date for enzyme replacement therapy by three months so agency can review chemistry, manufacturing and controls information; another drug, Strensiq, is also pending at FDA without any action.
You may also be interested in...
Alexion Gets Second Priority Review Voucher With Approval Of Rare Enzyme Disorder Drug
Kanuma, the first approved treatment for lysosomal acid lipase deficiency, will launch in January at an average annual treatment cost of $310,000.
Priority Review Voucher Not For Sale, Alexion Says After Strensiq Approval
Alexion plans to use voucher for one of its own products and might be targeting its next-generation version of blockbuster Soliris.
Keeping Track: Four Novel Agents Clear FDA; Two Complete Response Letters Issued
The latest drug development news and highlights from our FDA Performance Tracker.